Skip to main content

Table 1 Baseline tumour, patient and treatment characteristics for all patients (n = 26)

From: Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study

Characteristic All patients (n = 26)
Age at registration—median (min, max) 68.7 (43.5, 82.9)
Gender—n(%)  
Male 13 (50.0)
Female 13 (50.0)
Primary lung location—n(%)  
Left upper lobe 2 (7.7)
Left lower lobe 3 (11.5)
Right upper lobe 13 (50.0)
Right middle lobe 4 (15.4)
Right lower lobe 4 (15.4)
Pre-treatment size (cm)—mean ± SD 2.8 ± 1.1
T stage—n(%)  
T1 20 (76.9)
T2 6 (23.1)
Histology—n(%)  
Adenocarcinoma 16 (61.5)
Squamous 9 (34.6)
NSCLC NOS 1 (3.9)
Pre-treatment FEV1—mean ± SD 73.7 ± 16.4
Post-treatment FEV1—mean ± SD 75.1 ± 20.2
Change FEV1—mean ± SD 0.1 ± 13.5
Dose fractionation—n(%)  
54 Gy in 3 fractions 5 (19.2)
55 Gy in 5 fractions 15 (57.7)
60 Gy in 8 fractions 6 (23.1)
Surgery—n(%) 26 (100)
Surgery type—n(%)  
Lobectomy 18 (69.2)
Wedge resection 8 (30.8)
Surgical approach—n(%)  
VATS 21 (80.8)
VATS converted to open 3 (11.5)
Open 2 (7.7)
  1. NSCLC NOS non-small cell lung cancer not otherwise specified; FEV1 forced expiratory volume in 1 s, VATS video-assisted thoracoscopic surgery